BHVN logo

Biohaven Pharmaceutical Holding (BHVN) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

23 September 2022

Indexes:

Not included

Description:

Biohaven Pharmaceutical Holding is a biopharmaceutical company focused on developing innovative treatments for neurological and psychiatric disorders. They aim to improve the lives of patients through advanced therapies, particularly in areas like migraine and other central nervous system conditions.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

26 Nov '24 HC Wainwright & Co.
Buy
25 Nov '24 RBC Capital
Outperform
14 Nov '24 HC Wainwright & Co.
Buy
13 Nov '24 TD Cowen
Buy
13 Nov '24 RBC Capital
Outperform
19 Aug '24 Cantor Fitzgerald
Overweight
13 Aug '24 UBS
Buy
12 Aug '24 Cantor Fitzgerald
Overweight
24 July '24 Morgan Stanley
Overweight
18 June '24 RBC Capital
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
BHVN
prnewswire.com02 October 2024

NEW HAVEN, Conn. , Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd.

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
BHVN
prnewswire.com01 October 2024

NEW HAVEN, Conn. , Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd.

Biohaven Announces Proposed Public Offering of Common Shares
Biohaven Announces Proposed Public Offering of Common Shares
Biohaven Announces Proposed Public Offering of Common Shares
BHVN
prnewswire.com30 September 2024

NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Biohaven Ltd.

BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
BHVN
zacks.com24 September 2024

The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.

Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
BHVN
marketbeat.com24 September 2024

Biohaven Ltd. NYSE: BHVN has taken center stage in the biopharmaceutical sector after releasing positive results from its Phase 3 clinical trial for troriluzole, a drug being developed to treat spinocerebellar ataxia (SCA).

Overlooked Stock: BHVN
Overlooked Stock: BHVN
Overlooked Stock: BHVN
BHVN
youtube.com23 September 2024

Biohaven (BHVN) shares surged after the company's troriluzole drug showed significant slowed progression of spinocerebellar ataxia, a rare neurological disease. George Tsilis shares how the promising results can mark the beginning of a long road to success for Biohaven.

Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug
Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug
Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug
BHVN
investopedia.com23 September 2024

Biohaven (BHVN) shares soared 15% Monday after the biotech firm announced positive results from a study of its experimental treatment for a rare neurological condition.

Biohaven's stock surges as treatment slows progress of neurological disorder
Biohaven's stock surges as treatment slows progress of neurological disorder
Biohaven's stock surges as treatment slows progress of neurological disorder
BHVN
marketwatch.com23 September 2024

Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed progress of the condition in a clinical trial.

Biohaven's genetic disease drug meets main trial goal
Biohaven's genetic disease drug meets main trial goal
Biohaven's genetic disease drug meets main trial goal
BHVN
reuters.com23 September 2024

Biohaven has met the main goal in a study evaluating its drug in patients with an inherited disease that mainly affects the brain, the company said on Monday.

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
BHVN
prnewswire.com20 September 2024

Conference call and webcast to be held Monday, September 23, at 8:30am ET  NEW HAVEN, Conn. , Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the primary business of Biohaven Pharmaceutical Holding?
  • What is the ticker symbol for Biohaven Pharmaceutical Holding?
  • Does Biohaven Pharmaceutical Holding pay dividends?
  • What sector is Biohaven Pharmaceutical Holding in?
  • What industry is Biohaven Pharmaceutical Holding in?
  • What country is Biohaven Pharmaceutical Holding based in?
  • When did Biohaven Pharmaceutical Holding go public?
  • Is Biohaven Pharmaceutical Holding in the S&P 500?
  • Is Biohaven Pharmaceutical Holding in the NASDAQ 100?
  • Is Biohaven Pharmaceutical Holding in the Dow Jones?
  • When was Biohaven Pharmaceutical Holding's last earnings report?
  • When does Biohaven Pharmaceutical Holding report earnings?
  • Should I buy Biohaven Pharmaceutical Holding stock now?

What is the primary business of Biohaven Pharmaceutical Holding?

Biohaven Pharmaceutical Holding is a biopharmaceutical company focused on developing innovative treatments for neurological and psychiatric disorders. They aim to improve the lives of patients through advanced therapies, particularly in areas like migraine and other central nervous system conditions.

What is the ticker symbol for Biohaven Pharmaceutical Holding?

The ticker symbol for Biohaven Pharmaceutical Holding is NYSE:BHVN

Does Biohaven Pharmaceutical Holding pay dividends?

No, Biohaven Pharmaceutical Holding does not pay dividends

What sector is Biohaven Pharmaceutical Holding in?

Biohaven Pharmaceutical Holding is in the Healthcare sector

What industry is Biohaven Pharmaceutical Holding in?

Biohaven Pharmaceutical Holding is in the Biotechnology industry

What country is Biohaven Pharmaceutical Holding based in?

Biohaven Pharmaceutical Holding is headquartered in United States

When did Biohaven Pharmaceutical Holding go public?

Biohaven Pharmaceutical Holding's initial public offering (IPO) was on 23 September 2022

Is Biohaven Pharmaceutical Holding in the S&P 500?

No, Biohaven Pharmaceutical Holding is not included in the S&P 500 index

Is Biohaven Pharmaceutical Holding in the NASDAQ 100?

No, Biohaven Pharmaceutical Holding is not included in the NASDAQ 100 index

Is Biohaven Pharmaceutical Holding in the Dow Jones?

No, Biohaven Pharmaceutical Holding is not included in the Dow Jones index

When was Biohaven Pharmaceutical Holding's last earnings report?

Biohaven Pharmaceutical Holding's most recent earnings report was on 12 November 2024

When does Biohaven Pharmaceutical Holding report earnings?

The next expected earnings date for Biohaven Pharmaceutical Holding is 28 February 2025

Should I buy Biohaven Pharmaceutical Holding stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions